Gilead Sciences, Inc（GILD）の財務GILDGilead Sciences, Inc

Gilead Sciences, Inc. (GILD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Biktarvy, accounting for 48.3% of total sales, equivalent to $3.77B. Other significant revenue streams include Descovy and Trodelvy. Understanding this composition is critical for investors evaluating how GILD navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Gilead Sciences, Inc. maintains a gross margin of 79.76%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 32.76%, while the net margin is -134.51%. These profitability ratios, combined with a Return on Equity (ROE) of -20.57%, provide a clear picture of how effectively GILD converts its operational activities into shareholder value.

In the context of the broader market, GILD competes directly with industry leaders such as AMGN and GMAB. With a market capitalization of $190.38B, it holds a significant position in the sector. When comparing efficiency, GILD's gross margin of 79.76% stands against AMGN's 72.64% and GMAB's 92.73%. Such benchmarking helps identify whether Gilead Sciences, Inc. is trading at a premium or discount relative to its financial performance.

Gilead's financial performance shows a gross margin of 79.76% in Q2 2026, which is strong, although it reported a significant net income loss in the same quarter.